Biotest recorded revenues of EUR 218 million in 2004
Biotest recorded sales of EUR 218 million last financial year despite the difficult market environment. Sales were down only slightly on the previous year ( - 2%). The primary factors behind this development were the company's conscious reserved reaction on tender markets for plasma products that are characterized by strong price pressure, and the US dollar exchange rate, which did not bide well for export business. In particular, revenues were down in South America, Asia and the Middle East. Revenue growth in Germany (+ 5%) and on European markets (+ 10%) was surpassed by developments on these foreign markets. As a result, the proportion of German to group revenues thus increased slightly in 2004 from 33% to 35%.
The lower revenues were exclusively recorded in the Pharmaceutical division. Revenues in this division totaled EUR 142 million, with 3% less than in the previous year (EUR 146 million).
In contrast, the Diagnostic division was able to stabilize revenues at EUR 76 million, at the same level as the previous year, in the face of a market distinguished by competition for prices. Sales growth in Germany offset a slight downturn abroad.
Other news from the department business & finance
